Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.
P. B. Chapman
Consultant or Advisory Role - Roche
Research Funding - Roche
A. Hauschild
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
C. Robert
Consultant or Advisory Role - Roche
J. M. G. Larkin
No relevant relationships to disclose
J. B. A. G. Haanen
No relevant relationships to disclose
A. Ribas
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
D. Hogg
Consultant or Advisory Role - Roche
S. O'Day
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
P. A. Ascierto
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Schering-Plough
Honoraria - Bristol-Myers Squibb; Schering-Plough
A. Testori
No relevant relationships to disclose
P. Lorigan
No relevant relationships to disclose
R. Dummer
Consultant or Advisory Role - Roche
J. A. Sosman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
C. Garbe
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; GlaxoSmithKline; NSD; Roche; SOBI
Honoraria - Bristol-Myers Squibb; NSD; Roche; SOBI
Research Funding - Bristol-Myers Squibb; Genentech; Merck Sharp & Dohme; Roche; SOBI
R. J. Lee
Employment or Leadership Position - Roche
K. B. Nolop
No relevant relationships to disclose
B. Nelson
Employment or Leadership Position - Genentech
J. Hou
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
K. T. Flaherty
Consultant or Advisory Role - Genentech
G. A. McArthur
No relevant relationships to disclose